Standard BioTools (NASDAQ:LAB) Upgraded at Zacks Research

Zacks Research upgraded shares of Standard BioTools (NASDAQ:LAB) to a hold rating in a research note published on Thursday,Zacks.com reports.

A number of other research firms have also weighed in on LAB. Wall Street Zen lowered Standard BioTools from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 8th. TD Cowen dropped their price target on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating for the company in a research report on Wednesday, November 5th. Cowen lowered shares of Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Standard BioTools in a research note on Wednesday, October 8th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $1.35.

Standard BioTools Stock Down 2.0%

Shares of NASDAQ:LAB opened at $1.45 on Thursday. The stock has a market cap of $557.63 million, a PE ratio of -4.26 and a beta of 1.24. The company’s fifty day moving average is $1.32 and its 200 day moving average is $1.28. Standard BioTools has a 52 week low of $0.92 and a 52 week high of $2.25.

Insider Activity at Standard BioTools

In related news, Director Casdin Partners Master Fund, L purchased 150,000 shares of Standard BioTools stock in a transaction that occurred on Thursday, December 4th. The shares were bought at an average price of $1.45 per share, for a total transaction of $217,500.00. Following the completion of the transaction, the director directly owned 72,100,000 shares of the company’s stock, valued at $104,545,000. This represents a 0.21% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have bought 11,225,000 shares of company stock valued at $14,408,250. Company insiders own 23.16% of the company’s stock.

Institutional Trading of Standard BioTools

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Standard BioTools by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 17,225,250 shares of the company’s stock worth $18,603,000 after acquiring an additional 69,104 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Standard BioTools by 4.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,443,060 shares of the company’s stock worth $2,639,000 after purchasing an additional 110,411 shares during the period. Nuveen LLC bought a new position in Standard BioTools in the first quarter worth $862,000. HighTower Advisors LLC raised its holdings in Standard BioTools by 10.8% in the first quarter. HighTower Advisors LLC now owns 102,791 shares of the company’s stock worth $111,000 after purchasing an additional 10,000 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new position in Standard BioTools during the first quarter valued at $274,000. 53.74% of the stock is owned by institutional investors.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.